### Table of Contents

#### FROM THE EDITOR

**The battle of the clot**

In this issue we review two situations in which low-molecular-weight heparins have special advantages: in pregnant women and in patients with cancer.

B.F. MANDELL

#### MEDICAL GRAND ROUNDS

**A facial cutaneous horn**

A healthy 84-year-old woman has an asymptomatic lesion on her cheek that has grown progressively over the past 10 months. What is it?

S. VAÑÓ-GALVÁN, A. MARQUÉS, E. MUÑOZ-ZATO, AND P. JAÉN

**Autosomal dominant polycystic kidney disease: Emerging concepts of pathogenesis and new treatments**

Some of the mystery of autosomal dominant polycystic kidney disease is starting to clear. As a result, some promising new treatments are in clinical trials.

W.E. BRAUN

#### MEDICAL PROBLEMS IN PREGNANCY

**Anticoagulants and pregnancy:**

When are they safe?

Thrombotic risk is higher in pregnancy, and some women need anticoagulant therapy. Unfractionated heparin and low-molecular-weight heparins are effective and safe, with caveats.

P.S. GIBSON AND R. POWRIE

CONTINUED ON PAGE 76
Cancer and clots: All cases of venous thromboembolism are not treated the same

Idiopathic venous thromboembolism can be the first sign of cancer, although how extensively one should search for cancer in these cases is not clear.

B. BABU AND T.L. CARMAN

Lupus update: Perspective and clinical pearls

Patients with systemic lupus erythematosus have a markedly better survival rate today, but they face a greater risk of cancer, cardiovascular disease, and osteoporosis at early ages.

S. MANZI

Letters to the editor

Intensive therapy of type 2 diabetes (ACCORD trial)

Long QT syndrome

CME Calendar

Correction: Managing hepatitis B


2008 Reviewers

About our CME Self-test Online

To receive CME credit, read the selected articles in this issue and then go to www.ccjm.org to take the test. It should take about 1 hour and 30 minutes to complete this activity.

Release date: February 1, 2009.
Expiration date: January 31, 2010.